All lobbying filings

ARNOLD & PORTER KAYE SCHOLER LLP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Income

$80,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4231
Treat and Reduce Obesity Act of 2025
S 1973
Treat and Reduce Obesity Act of 2025

Lobbying activity 4

Pharmacy

Issues related to general compounding.

Health Issues

Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973).

Consumer Issues/Safety/Products

Issues related to general compounding.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.